Has Naomi Fisher, MD received payments from drug or device companies?

Yes. Drug and device makers reported $79,111 in general payments to Naomi Fisher, MD across 79 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Naomi Fisher, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Naomi Fisher, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Naomi Fisher, MD

Endocrinology, Diabetes & Metabolism · Boston, MANPI 1770540072

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (51.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Medtronic at 57.2% of the total. 2025 is the largest year on record at $24,444, 3.9 times the $6,300 reported in 2021. Among endocrinology, diabetes & metabolism clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$79,111in general payments, 2019–2025

Across 79 payments — averaging $1001.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$45K
Recor Medical Inc$19K
Boston Scientific$6K
Janssen Scientific Affairs, LLC$5K
Astrazeneca UK Limited$3K
AstraZeneca$1K
plus $60 from 1 others

$500,287in research payments, 2019–2025

Across 67 payments — averaging $7466.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Recor Medical Inc$500K

What the payments were for

Consulting fees$40,83352%
Speaking & faculty fees$26,51334%
Travel & lodging$10,70214%
Food & beverage$1,0641%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic	46	$45,235
Recor Medical Inc	22	$18,698
Boston Scientific	3	$6,033
Janssen Scientific Affairs, LLC	2	$4,522
Astrazeneca UK Limited	2	$3,222
AstraZeneca	2	$1,343
Alnylam Pharmaceuticals Inc.	2	$60

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Paradise Ultrasound Renal Denervation System$18,290
GENERAL - THERAPIES$6,000
Resolute$3,150

How this compares

$79,111 in reported general payments places this provider in the 95th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.

See all endocrinology, diabetes & metabolism providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$14,934

Medicare patients

Services billed

173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Eplerenone	11	$2,008
Irbesartan	45	$1,071
Olmesartan Medoxomil	14	$940
Felodipine ErFelodipine	33	$928
Amlodipine Besylate	71	$712
Labetalol Hcl	19	$341
Hydrochlorothiazide	12	$218
Atorvastatin Calcium	20	$188
Spironolactone-HctzSpironolact/Hydrochlorothiazid	13	$172
Spironolactone	28	$134
Lisinopril	19	$124

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Boston

Jason GagliaBoston$2.4M
Vanita ArodaBoston$482K
Michael RosenblattBoston$447K
Steven RussellBoston$445K
Beverly BillerBoston$346K
Christos MantzorosBoston$243K
Augusto Caballero-RoblesBoston$150K
Osama HamdyBoston$117K
Barbara KahnBoston$105K
Andrea CovielloBoston$67K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →